Skip to main content
Isomer
  1. Home
  2. Automated
  3. NDF A-Z listing
  4. Panitumumab [Vectibix]
P

Panitumumab [Vectibix]

Subsidy Information and Financing Scheme

SDL

MSHL

Drug Guidance

Yes

Post-marketing information

Yes

Summary of Biologics

No

Active ingredient: Panitumumab

General information

Subsidy Information and Financing Scheme

[SDL] Panitumumab (Vectibix) Concentrate For Infusion 100 mg/5 mL

[MSHL] Panitumumab Concentrate For Solution For Infusion 100 mg/5 mL

  1. For cancer treatment.

Legend

This section shows the following:

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

Legend list

Indicator

Legend

SDL

Standard Drug List

MAF

Medical Assistance Fund

SVL

Subsidised Vaccine List

MSHL

Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

Drug Guidance for Subsidy

12/07/2022 Cetuximab and panitumumab for treating RAS wild-type colorectal cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Cetuximab 100 mg/20 mL solution for infusion; and

  • Panitumumab 100 mg/5 mL concentrate for solution for infusion

as monotherapy or in combination with chemotherapy for treating RAS wild-type metastatic colorectal cancer.

Subsidy status

[R] Panitumumab 100 mg/5 mL concentrate for solution for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.

[R] Cetuximab 100 mg/20 mL solution for infusion is recommended for inclusion on the SDL for the abovementioned indication with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Legend list

Indicator

Legend

R

Recommended for subsidy

NR

Not recommended for subsidy

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Drug availability

Formulation

Public Healthcare Institution

Vectibix Concentrate For Infusion 100 mg/5 mL

  1. Khoo Teck Puat Hospital

  2. National Cancer Centre

  3. Ng Teng Fong General Hospital

  4. National University Hospital

  5. Tan Tock Seng Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated

monthly, please refer to HSA Infosearch for the most updated product information.

Intravenous

Back to top